KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $258.0 million.

  • Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) rose 3.88% to $258.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $258.0 million, marking a year-over-year increase of 3.88%. This contributed to the annual value of $258.0 million for FY2025, which is 3.88% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $258.0 million, which was up 3.88% from $258.6 million recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $261.9 million during Q1 2021, and registered a low of $257.9 million during Q1 2022.
  • In the last 5 years, Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $259.7 million in 2021 and averaged $259.7 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) plummeted by 152.73% in 2022 and then soared by 93.06% in 2023.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $259.9 million in 2021, then dropped by 0.31% to $259.1 million in 2022, then grew by 0.54% to $260.5 million in 2023, then decreased by 1.0% to $257.9 million in 2024, then rose by 0.04% to $258.0 million in 2025.
  • Its last three reported values are $258.0 million in Q4 2025, $258.6 million for Q3 2025, and $259.2 million during Q2 2025.